서울대학교 중앙도서관
S-Space 소개
My S-Space
로그인이 필요합니다.
Login

S-Space

Browse

Publisher

Jump to a point in the index
Or type in a year

  • Sort by
  • In order
  • Results/Page
  • Authors/record

Showing results 121 to 155 of 155

Issue DateTitle / Author(s) / CitationFileAltmetrics
2018-12
nCirculating biomarkers and resistance to endocrine therapy in metastatic breast cancers: Correlative results from AZD9496 oral SERD phase I trial
DOI
2018-12
Androgen receptor inhibitor enhances the antitumor effect of PARP inhibitor in breast cancer cells by modulating DNA damage response
DOI
2019-02
Tumor-Associated Macrophages Enhance Tumor Hypoxia and Aerobic Glycolysis
DOI
2019-06
Phase I study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) administered with PD-L1 inhibitor (atezolizumab) in advanced solid tumors
DOI
2019-07
Therapeutic efficacy of ABN401, highly selective c-MET inhibitor, in NSCLC with MET-amplified AND/OR EGFR mutation
DOI
2020-01
Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naive Metastatic Breast Cancer
DOI
2020-02
Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
DOI
2020-03
Clinical Application of Next-Generation Sequencing-Based Panel to BRAF Wild-Type Advanced Melanoma Identifies Key Oncogenic Alterations and Therapeutic Strategies
view fileDOI
2020-03
Breast Cancer Cell-Derived Soluble CD44 Promotes Tumor Progression by Triggering Macrophage IL1 beta Production
DOI
2020-07
Safety and Tolerability of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Asian Patients with Pretreated Recurrent or Refractory Gastric Cancer
DOI
2020-10
Glomerular Hyperfiltration and Cancer: A Nationwide Population-Based Study
DOI
2021-02
Phase II Study of Avelumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib
DOI
2021-03
Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial
DOI
2021-04
Efficacy of pembrolizumab monotherapy for advanced gastric/gastroesophageal junction cancer with programmed death ligand 1 combined positive score ≥10
DOI
2021-04
Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody
DOI
2021-06
A Clinically Applicable 24-Protein Model for Classifying Risk Subgroups in Pancreatic Ductal Adenocarcinomas using Multiple Reaction Monitoring-Mass Spectrometry
DOI
2021-07
Circulating Small Extracellular Vesicles Activate TYRO3 to Drive Cancer Metastasis and Chemoresistance
DOI
2021-11
Pharmacokinetics, Safety, and Efficacy of Trastuzumab Deruxtecan with Concomitant Ritonavir or Itraconazole in Patients with HER2-Expressing Advanced Solid Tumors
DOI
2021-12
Safety and Antitumor Activity of α-PD-L1 Antibody as Monotherapy or in Combination with α-TIM-3 Antibody in Patients with Microsatellite Instability-High/Mismatch Repair-Deficient Tumors
DOI
2022-01
A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer
DOI
2022-03
Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2(-) Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial
DOI
2022-06
Large-scale Integrated Analysis of Genetics and Metabolomic Data Reveals Potential Links Between Lipids and Colorectal Cancer Risk

Shu, Xiang; Chen, Zhishan; Long, Jirong; Guo, Xingyi; Yang, Yaohua; Qu, Conghui; Ahn, Yoon-Ok; Cai, Qiuyin; Casey, Graham; Gruber, Stephen B.; Huyghe, Jeroen R.; Ha Jee, Sun; Jenkins, Mark A.; Jia, Wei-Hua; Jung, Keum Ji; Kamatani, Yoichiro; Kim, Dong-Hyun; Kim, Jeongseon; Kweon, Sun-Seog; Le Marchand, Loic; Matsuda, Koichi; Matsuo, Keitaro; Newcomb, Polly A.; Oh, Jae Hwan; Ose, Jennifer; Oze, Isao; Pai, Rish K.; Pan, Zhi-Zhong; Pharoah, Paul D. P.; Playdon, Mary C.; Ren, Ze-Fang; Schoen, Robert E.; Shin, Aesun; Shin, Min-Ho; Shu, Xiao-Ou; Sun, Xiaohui; Tangen, Catherine M.; Tanikawa, Chizu; Ulrich, Cornelia M.; van Duijnhoven, Franzel J. B.; Van Guelpen, Bethany; Wolk, Alicja; Woods, Michael O.; Wu, Anna H.; Peters, Ulrike; Zheng, Wei

Cancer Epidemiology Biomarkers and Prevention, Vol.31 No.6, pp.1216-1226

DOI
2022-06
ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with ALK-Positive Non-Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges
DOI
2022-08
Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2(- )ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study
DOI
2022-08
Association of Tumor Mutational Burden with Efficacy of Pembrolizumab±Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study
DOI
2022-08
First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors
DOI
2022-09
Randomized, Double-Blind, Placebo-Controlled Phase III Study of Paclitaxel +/- Napabucasin in Pretreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
DOI
2022-09
Association between Body Mass Index and Risk of Gastric Cancer by Anatomic and Histologic Subtypes in Over 500,000 East and Southeast Asian Cohort Participants
DOI
2023-04
Tumor-agnostic efficacy and safety of dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: ROAR basket study
DOI
2023-05
Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis
DOI
2023-07
Associations between Physical Activity and Incidence of Cancer among Overweight Adults in Korea: Results from the Health Examinees-G Study

Choi, Jaesung; Park, JooYong; Kim, Ji-Eun; Lee, Miyoung; Kang, Daehee; Shin, Aesun; Choi, Ji-Yeob

Cancer Prevention Research, Vol.16 No.7, pp.405-418

DOI
2023-08
BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non-Small Cell Lung Cancer
DOI
2023-08
Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens
DOI
2023-10
ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2–Positive Gastric or Gastroesophageal Junction Adenocarcinoma
DOI
2024
Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study
DOI
1 2 3 4